2:23 PM
 | 
May 03, 2019
 |  BioCentury  |  Emerging Company Profile

Vineti: Keeping cell therapies on track

How Vineti's GMP-ready platform connects the cell therapy supply chain

Drawing on its experience with CAR T cell therapies, Vineti has developed a cloud-based software platform that standardizes processes and drives down costs in the supply chain for personalized medicines.

According to Vineti Inc. CEO Amy DuRoss, the company was incubated at GE Ventures after an undisclosed company approached the investor in 2014 about a CAR T cell therapy then in clinical trials.

“They realized it really presented them with the most complex supply chain of logistics workflow requirements in the history of biologics -- really, in the history of medicine,” said DuRoss, who co-founded the start-up when she was at GE Ventures.

This was the first time single-batch GMP processes had to occur at the point of care for trials and marketed personalized medicines, and that created a need for GMP-level oversight of cell handling and the orchestration of material handoffs between multiple stakeholders, she said.

Autologous CAR T cell therapies such as Novartis AG’s Kymriah tisagenlecleucel and Gilead Sciences Inc.’s Yescarta axicabtagene also involve challenges with...

Read the full 821 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >